Display options
Share it on

Urol Case Rep. 2014 Jun 28;2(5):147-9. doi: 10.1016/j.eucr.2014.05.011. eCollection 2014 Sep.

Stereotactic Body Radiotherapy for the Treatment of Renal Tumors.

Urology case reports

Michael Hanzly, Terrance Creighton, Michael Mix, Kevin Zeeck, Simon Fung-Kee-Fung, Anurag K Singh, Thomas Schwaab

Affiliations

  1. Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.

PMID: 26958469 PMCID: PMC4782072 DOI: 10.1016/j.eucr.2014.05.011

Abstract

The purpose of this study was to evaluate the response of actively growing renal masses to stereotactic body radiation therapy (SBRT). We retrospectively reviewed our institutional review board-approved kidney database and identified 4 patients who underwent SBRT, 15 Gy dose, for their rapidly growing renal masses. Three patients had a decreased tumor size after radiation treatment by 20.8%, 38.1%, and 20%. The other patient had a size gain of 5.6%. This patient maintained a similar tumor growth rate before and after SBRT. Mean follow-up time was 13.8 months. SBRT represents an effective management option in select patients with larger rapidly growing kidney masses.

Keywords: Kidney; Oncology; Radiotherapy; Tumor

References

  1. Science. 2003 May 16;300(5622):1155-9 - PubMed
  2. Surg Innov. 2007 Dec;14 (4):265-9 - PubMed
  3. Eur Urol. 2011 Jul;60(1):39-44 - PubMed

Publication Types